Onconetix (NASDAQ:ONCO – Get Free Report) and AstraZeneca (NASDAQ:AZN – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations and profitability.
Insider & Institutional Ownership
23.9% of Onconetix shares are owned by institutional investors. Comparatively, 20.4% of AstraZeneca shares are owned by institutional investors. 1.0% of Onconetix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of recent recommendations for Onconetix and AstraZeneca, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Onconetix | 1 | 0 | 0 | 0 | 1.00 |
| AstraZeneca | 1 | 0 | 10 | 0 | 2.82 |
Profitability
This table compares Onconetix and AstraZeneca’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Onconetix | -4,011.43% | -632.63% | -160.97% |
| AstraZeneca | 16.17% | 32.89% | 13.00% |
Earnings and Valuation
This table compares Onconetix and AstraZeneca”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Onconetix | $2.52 million | 0.83 | -$58.69 million | $10.89 | 0.12 |
| AstraZeneca | $58.13 billion | 10.02 | $7.04 billion | $3.01 | 62.35 |
AstraZeneca has higher revenue and earnings than Onconetix. Onconetix is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Onconetix has a beta of 3.45, indicating that its share price is 245% more volatile than the S&P 500. Comparatively, AstraZeneca has a beta of 0.34, indicating that its share price is 66% less volatile than the S&P 500.
Summary
AstraZeneca beats Onconetix on 10 of the 14 factors compared between the two stocks.
About Onconetix
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Receive News & Ratings for Onconetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconetix and related companies with MarketBeat.com's FREE daily email newsletter.
